
Shire has acquired Foresight Biotherapeutics for $300 million, as it looks to build its presence in eye diseases. The acquisition …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

